| 1 | PLOTKIN S A, CADOZ M, MEIGNIER B, et al.. The Safety and use of canarypox vectored vaccine[J]. Dev. Biol. Stand., 1995, 84(1): 165-170. | 
																													
																							| 2 | LUNDSTROM K. Viral vectors in gene therapy[J/OL]. Diseases, 2018, 6: 42[2021-11-26]. . | 
																													
																							| 3 | PAILLOT R, RASH N L, GARRETT D, et al.. How to meet the last OIE expert surveillance panel recommendations on equine Influenza (EI) vaccine composition: a review of the process required for the recombinant canarypox-based EI vaccine[J/OL]. Pathogens, 2016, 5: 64[2021-11-26]. . | 
																													
																							| 4 | MINKE J M,EL-HAGE C M,TAZAWA P, et al.. Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine shortened interdose intervals and vaccination of young foals[J]. Aus. Vet. J., 2011, 89(S): 137-139. | 
																													
																							| 5 | ADAMS A A, STURGILL T L, BREATHNACH C C, et al.. Humoral and cell-mediated immune responses of old horses following recombinant Canarypox virus vaccination and subsequent challenge infection[J].Vet. Immunol. Immunopathol., 2011, 139(1): 128-140. | 
																													
																							| 6 | KARACA K, DUBOVI E J, SIGER L, et al.. Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs[J]. AJVR, 2007, 68(2): 208-212. | 
																													
																							| 7 | STITTELAAR K J, LACOMBE V, LAVIEREN R, et al.. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine[J]. Vaccine, 2010, 28(36): 4970-4976. | 
																													
																							| 8 | COKE R L, BACKUES K A, HOOVER J P, et al.. Serologic responses after vaccination of fennec foxes (Vulpes zerda) and meerkats (Suricata suricatta) with a live, canarypox-vectored canine distemper virus vaccine[J]. J. Zoo Wildl. Med., 2005, 36(2): 326-330. | 
																													
																							| 9 | BRONSON E, DEEM S L, SANCHEZ C, et al. Serologic response to a canarypox-vectored Canine distemper virus vaccine in the giant panda (Ailuropoda melanoleuca)[J]. J. Zoo Wildl. Med., 2007, 38(2): 363-366. | 
																													
																							| 10 | TAYLOR J, WEINBERG R, TARTAGLIA J, et al.. Nonreplicating viral vectors as potential vaccines:recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins[J]. Virol, 1992, 187(2): 321-328. | 
																													
																							| 11 | WEINGARTL H M, BERHANE Y, CASWELL J L, et al.. Recombinant Nipah virus vaccines protect pigs against challenge[J]. J. Virol., 2006, 80(16): 7929-7938. | 
																													
																							| 12 | GUILLAUME-VASSELIN V, LEMAITRE L, DHONDT K P, et al.. Protection from Hendra virus infection with canarypox recombinant vaccine[J/OL]. NPJ Vaccines, 2016, 1(20): 16003[2021-11-26]. . | 
																													
																							| 13 | COX W, TARTAGLIA J, PAOLETTI E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein[J]. Virol, 1993, 195(5): 845-850. | 
																													
																							| 14 | LIU J, YU Q G, STONE G W, et al.. CD40L expressed from the canarypox vector,ALVAC,can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals[J]. Vaccine, 2008, 26(18): 4062-4072. | 
																													
																							| 15 | Aids Vaccine Evaluation Group022Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120[J]. J. Infect. Dis., 2001, 183(3): 563-570. | 
																													
																							| 16 | PERKS-NGARM S, PITISUTTITHUM P, NITAYAPHAN S, et al.. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[J]. N. Engl. J. Med., 2009, 361(11): 2209-2220. | 
																													
																							| 17 | KIM J H, EXCLER J L, MICHAEL N L. Lessons from the RV144 Thai phase Ⅲ HIV-1 vaccine trial and the search for correlates of protection[J]. Annu. Rev. Med., 2015, 66(2): 423-437. | 
																													
																							| 18 | JIN X J, RAMANATHAN J M, BARSOUM S, et al.. Safety and immunogenicity of ALVAC VCP1452 and recombinant GP160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy[J]. J. Virol., 2002, 76(5): 2206-2216. | 
																													
																							| 19 | JOHNSON D C, McFARLAND E J, MURESAN P, et al.. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women[J]. J. Infect. Dis., 2005, 192(11): 2129-2133. | 
																													
																							| 20 | TEIGLER J E, PHOGAT S, FRANCHINI G, et al.. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys[J]. J. Virol., 2014, 88(3): 1809-1814. | 
																													
																							| 21 | POULET H, BRUNET S, BOULARAND C, et al.. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia[J].Vet. Rec., 2003, 153(1): 141-145. | 
																													
																							| 22 | GROSENBAUGH D A, LEARD T, PARDO C. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine[J]. J. Am. Vet. Med. Assoc., 2006, 228(4): 726-727. | 
																													
																							| 23 | SCHLECHT-LOUF G, MANGENEY M, EL-GARCH H, et al.. A targeted mutation within the Feline leukemia virus(FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine[J]. J. Virol., 2014, 88(5): 992-1001. | 
																													
																							| 24 | PATEL M, CARRITT K, LANE J, et al.. Comparative efficacy of Feline leukemia virus(FeLV) inactivated whole-virus vaccine and canarypox virus-vectored vaccine during virulent FeLV challenge and immunosuppression[J]. Clin. Vac. Immunol., 2015, 22(7): 798-805. | 
																													
																							| 25 | GUTHRIE A J, QUAN M, LOURENS C W, et al.. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus[J]. Vaccine, 2009, 27(25): 4434-4438. | 
																													
																							| 26 | GARCH H E, CRAFFORD J E E, AMOUYAL P, et al.. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses[J].Vet. Immunol. Immunopathol., 2012, 149(1): 76-85. | 
																													
																							| 27 | ZANETTI F A, GRAND M D C, MITAROTONDA R C, et al.. Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens[J]. Braz. J. Microbiol., 2014, 45(7): 1231-1234. | 
																													
																							| 28 | BOONE J D, BALASURIYA U B, KARACA K, et al.. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep[J]. Vaccine, 2007, 25(4): 672-678. | 
																													
																							| 29 | KARACA K, BOWEN R, AUSTGEN L E, et al.. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge[J]. Vaccine, 2005, 23(23): 3808-3813. | 
																													
																							| 30 | MINKE J M, SIGER L, CUPILLARD L, et al.. Protection provided by a recombinant ALVAC-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain[J]. Vaccine, 2011, 29(27): 4608-4612. | 
																													
																							| 31 | PANCHOLI P, LIU Q Y, TRICOCHE N, et al.. DNA prime-canarypox boost with polycistronic Hepatitis C virus(HCV) genes generates potent immune responses to HCV structural and nonstructural proteins[J]. J. Infect. Dis., 2000, 182(1): 18-27. | 
																													
																							| 32 | PANCHOLI P,PERKUS M, TRICOCHE N, et al.. DNA immunization with Hepatitis C virus(HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-Vaccinia virus infection in HLA-A2.1-transgenic mice[J]. J. Virol., 2003, 77(1): 382-390. | 
																													
																							| 33 | BERNSTEIN D I, SCHLEISS M R, BERENCSI K, et al.. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus(CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults[J]. J. Infect. Dis., 2002, 18(S): 486-490. | 
																													
																							| 34 | MINKE J M, FISCHER L, BAUDU P H, et al.. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine Herpes virus vaccination[J].Vet. Immunol. Immunopathol., 2006, 111(1): 47-57. | 
																													
																							| 35 | JAS D, COUPIER C, TOULERMONDE C E, et al.. Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant Rabies virus vaccine[J]. Vaccine, 2012, 30(49): 6991-6996. | 
																													
																							| 36 | MARROW J C, PADILLA L R, HAYEK L A C, et al.. Comparison of antibody response to a non-adjuvanted live canarypox-vectored recombinant rabies vaccine and a killed adjuvanted rabies vaccine in Eld's deer(rucervus eldithamin)[J]. J. Zoo Wildl. Med., 2014, 45(2): 315-320. | 
																													
																							| 37 | FISCHER L, LE GROS F X, MASON P W, et al.. A recombinant canarypox virus protects rabbits against a lethal Rabbit hemorrhagic disease virus (RHDV) challenge[J]. Vaccine, 1997, 15(1): 90-96. | 
																													
																							| 38 | ABBEHUSEN M M C, CUNHA J, SUAREZ M S, et al. Immunization of experimental dogs with salivary proteins from Lutzomyia longipalpis,using DNA and recombinant canarypox virus induces immune responses consistent with protection against leishmania infantum[J/OL]. Front. Immunol., 2019, 10: 1828[2021-11-26]. . |